Eiger Mountains
Corporate Profile
Eiger is a clinical-stage biopharmaceutical company committed to developing and commercializing novel products for the treatment of Orphan diseases. Eiger has built a diverse, late-stage portfolio of well-characterized product candidates with the potential to address diseases for which the unmet medical need is high, a novel biology for treatment has been identified, and for which an effective therapy is urgently needed. The Eiger management team has extensive experience in the clinical development... More >>
Stock Quote
EIGR (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$12.24
Change (%) Stock is Down 0.56 (4.38%)
Volume127,691
Data as of 10/23/17 2:12 p.m. ET
Refresh quote
Recent NewsMore >>
DateTitle
10/23/17Eiger Announces Positive Phase 2 Interim 24-Week Data with Pegylated Interferon Lambda in Hepatitis Delta Virus (HDV) Infection at the American Association for the Study of Liver Diseases (AASLD) Meeting
10/02/17Eiger Announces Abstracts and Presentations at the American Association for the Study of Liver Diseases (AASLD) Meeting
09/18/17Eiger Announces Appointment of Biopharmaceutical Industry Veteran Evan Loh, MD to its Board of Directors
09/05/17Eiger Announces FDA Orphan Drug Designation Granted for Pegylated Interferon Lambda in Hepatitis Delta Virus Infection
Upcoming EventsMore >>
DateTitle
11/15/17
through
11/16/17
Eiger BioPharmaceuticals at the Jeffries London Healthcare Conference
LocationWaldorf Hilton, London
11/28/17
through
11/29/17
Eiger BioPharmaceuticals at the Piper Jaffray Companies Healthcare Conference
LocationNYC Palace Hotel
New York, NY
What's New
There are currently no items available.
Receive E-mail Alerts
Sign up to receive e-mail alerts whenever Eiger BioPharmaceuticals posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed.